Last reviewed · How we verify
Single dose of PF-07220060 as second Tablet Formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Single dose of PF-07220060 as second Tablet Formulation (Single dose of PF-07220060 as second Tablet Formulation) — Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Single dose of PF-07220060 as second Tablet Formulation TARGET | Single dose of PF-07220060 as second Tablet Formulation | Pfizer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Single dose of PF-07220060 as second Tablet Formulation CI watch — RSS
- Single dose of PF-07220060 as second Tablet Formulation CI watch — Atom
- Single dose of PF-07220060 as second Tablet Formulation CI watch — JSON
- Single dose of PF-07220060 as second Tablet Formulation alone — RSS
Cite this brief
Drug Landscape (2026). Single dose of PF-07220060 as second Tablet Formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/single-dose-of-pf-07220060-as-second-tablet-formulation. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab